Patient Information Leaflet
Veriscal D Flas 1.500 mg/400 IU chewable tablets
(calcium carbonate/vitamin D3)
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
This medication is an association of calcium and vitamin D.
Veriscal D Flas is indicated for the treatment of vitamin D deficiency states in patients who require calcium supplementation, as well as a vitamin D and calcium supplement associated with certain osteoporosis treatments.
Do not take Veriscal D Flas
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Veriscal D Flas:
Other medications and Veriscal D Flas
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Certain medications may interact with this medication; in these cases, it may be necessary to change the dose, discontinue treatment with one of them, or wait at least a few hours between administration of both.
Veriscal D Flas with food, drinks, and alcohol
If you take this medication with foods and drinks containing oxalic acid (present in spinach and rhubarb) or phytic acid (present in whole wheat bread and whole grain cereals), interactions may occur, so it is recommended not to take this medication during the two hours following the consumption of foods with high oxalic acid and phytic acid content.
Pregnancy, breastfeeding, and fertility
The consumption of medications during pregnancy can be hazardous to the embryo and fetus.
During pregnancy and breastfeeding, the daily intake should not exceed 1500 mg of calcium and 600 IU of vitamin D3.
In pregnant women, excessive vitamin D intake should be avoided, as prolonged maintenance of high blood calcium levels could cause fetal abnormalities.
Driving and operating machinery
No effects on the ability to drive and operate machinery have been observed.
Veriscal D Flas contains aspartame, lactose, and saccharose
This medication contains 8.672 mg of aspartame in each 4.124 mg/g tablet.
Aspartame contains a source of phenylalanine that may be detrimental in cases of phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates due to the body's inability to eliminate it correctly.
This medication contains lactose. If your doctor has indicated that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains saccharose. If your doctor has indicated that you have an intolerance to certain sugars, consult with them before taking this medication. It may cause tooth decay.
Interactions with diagnostic tests
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Remember to take your medication. The recommended dose is:
Adults: 1-2 buccal tablets per day, preferably after meals.
Use in children and adolescents
Consult your doctor to individualize the dose.
To properly administer the medication, dissolve the tablet in the mouth, then drink a glass of water.
If you take more Veriscal D Flas than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you have taken more Veriscal D Flas than you should, consult your doctor or pharmacist immediately.
Intentional or accidental overdose with buccal tablets is unlikely.
If you forgot to take Veriscal D Flas
Do not take a double dose to compensate for the missed dose, simply take the missed dose when you remember and take the next doses with the indicated interval between doses (12 – 24 hours).
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people may experience them.
The following adverse effects have been observed:
Uncommon(may affect up to 1 in 1,000 people): constipation, gas, nausea, abdominal pain, and diarrhea.
Mild digestive disturbances may occasionally occur. Veriscal D Flas may stimulate the formation of kidney stones in patients with altered renal function.
If you consider any of the adverse effects you are experiencing to be severe or if you notice any adverse effect not mentioned in this prospectus, inform your doctor or pharmacist.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not store at a temperature above 86°F (30°C). Store in the original packaging.
Do not use this medication after the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Veriscal D Flas
The active principles are calcium carbonate and colecalciferol (vitamin D3).
Each tablet contains 1,500 mg of calcium carbonate equivalent to 600 mg of calcium and 400 IU of colecalciferol (vitamin D3) (equivalent to 0.01 mg).
The other components (excipients) are: anhydrous citric acid, maltodextrin, hydroxypropylcellulose, lactose monohydrate, stearic acid, aspartame (E951), orange aroma, gelatin, sucrose, cornstarch, partially hydrogenated soybean oil, all-rac-α-tocopherol, and silicon dioxide.
Appearance of the product and content of the packaging
Veriscal D Flas is presented in the form of buccal dispersible tablets for oral administration in containers of 60 tablets.
Holder of the marketing authorization
Laboratorios Farmacéuticos VALOMED, S.A.
C/ San Rafael, 3
28108 Alcobendas, Madrid
Spain
Responsible for manufacturing
ITALFARMACO S.p.A.
Viale Fulvio Testi, 330
20126 Milan
Italy
You can request more information about this medication by contacting the local representative of the marketing authorization holder
Italfarmaco, S.A.
C/ San Rafael, 3
28108 Alcobendas, Madrid
Spain
Last review date of this leaflet:May 2021.
The detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es).
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.